DIAGNOS Welcomes Mr. Vincent Duhamel and Mr. Robert J. Dunn to its Board of Directors
September 28 2020 - 1:11PM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:
ADK) (OTCQB: DGNOF), a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce the appointments of Mr.
Vincent Duhamel and Mr. Robert J. Dunn to the Corporation’s board
of directors (the “Board”).
Mr. Duhamel has an established track record in
overseeing start-up companies and restructuring operations, as well
as leading large investment teams in multi-cultural environments.
Mr. Duhamel is Vice Chairman of the board of directors of Fiera
Capital, a leading independent global asset management firm. Prior
to joining Fiera Capital, he held several senior positions in Asia
and Canada. Mr. Duhamel has played an active role on several boards
and committees, including at the CFA Institute and the Stock
Exchange of Hong Kong.
With 40 years of extensive experience in the
insurance business, Mr. Dunn brings expertise in, among others, the
financial and communications sectors. From 2017 to 2019, Mr. Dunn
held the position of Vice Chairman and Executive Vice President of
HUB International Québec Ltd.
“We are pleased that Vincent and Robert have
accepted to join the Board. I am convinced that their vast work
experience and business relationships will directly contribute to
the growth and success of our business,” said Mr. André Larente,
President of DIAGNOS.
The Board has approved a grant of 600,000 stock
options to Mr. Duhamel and a grant of 500,000 stock options to Mr.
Dunn. Stock options vest at 50% per year, commencing with the first
anniversary of the grant. The exercise price of these options has
been established at $0.285 per share. The expiry date to which
these options can be exercised has been fixed to September 28,
2025.
Furthermore, the Corporation announces the
resignation of Mr. Georges Hébert from his position as director and
chairman of the audit committee. The Board wishes to thank Mr.
Hébert for his contribution to the development of DIAGNOS.
The Corporation also announces that, subject to
regulatory acceptance, at the annual and special meeting of
shareholders held earlier today, the disinterested shareholders of
the Corporation approved a special resolution pursuant to which the
maximum number of common shares of the Corporation that may be
issued under the stock option plan be set at 9,000,000,
representing an increase of 3,000,000 common shares.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024